However, the response to neoadjuvant chemotherapy is poor in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer compared to HER2+ breast cancer or triple-negative breast cancer (TNBC) (3). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.